2022
Interim Clinical Utility Findings of a Transcriptomic Psoriasis Biologic Test Demonstrate Altered Physician Prescribing Behavior and Improved Patient Outcomes
Strober B, Bukhalo M, Armstrong A, Pariser D, Kircik L, Parhami S, Montgomery P, Dickerson T. Interim Clinical Utility Findings of a Transcriptomic Psoriasis Biologic Test Demonstrate Altered Physician Prescribing Behavior and Improved Patient Outcomes. SKIN The Journal Of Cutaneous Medicine 2022, 6: 458-462. DOI: 10.25251/skin.6.6.2.Peer-Reviewed Original ResearchPhysician prescribing behaviorPatient outcomesPsoriasis patientsPrescribing behaviorClinical utilityExact testMatch StudyChoice of biologicsFisher's exact testPhysician decision makingBiologic selectionBiologic-naïveClinical outcomesLesional skinPsoriasis treatmentDrug classesPatient responsePatient managementWeek 4PatientsPhysician behaviorPhysiciansHealthcare systemBaselineInterim measurementsSwitching to risankizumab from ustekinumab or adalimumab in plaque psoriasis patients improves PASI and DLQI outcomes for sub-optimal responders
Strober B, Armstrong A, Rubant S, Patel M, Wu T, Photowala H, Crowley J. Switching to risankizumab from ustekinumab or adalimumab in plaque psoriasis patients improves PASI and DLQI outcomes for sub-optimal responders. Journal Of Dermatological Treatment 2022, 33: 2991-2996. PMID: 35839335, DOI: 10.1080/09546634.2022.2095328.Peer-Reviewed Original ResearchConceptsPsoriasis Area Severity IndexPASI 75Plaque psoriasis patientsSevere plaque psoriasisSub-optimal respondersPost Hoc AnalysisSignificant safety eventsPASI 50Plaque psoriasisBiologic therapyPASI scorePsoriasis patientsWashout periodIncomplete responsePatientsSafety eventsSeverity IndexPsoriasisDosesSuboptimal resultsSignificant safety riskDLQIAdalimumabPartial success
2021
Signal Detection and Methodological Limitations in a Real-World Registry: Learnings from the Evaluation of Long-Term Safety Analyses in PSOLAR
Bissonnette R, Gottlieb A, Langley R, Leonardi C, Papp K, Pariser D, Uy J, Lafferty K, Langholff W, Fakharzadeh S, Berlin J, Brouwer E, Greenspan A, Strober B. Signal Detection and Methodological Limitations in a Real-World Registry: Learnings from the Evaluation of Long-Term Safety Analyses in PSOLAR. Drug Safety 2021, 44: 699-709. PMID: 34075572, PMCID: PMC8184557, DOI: 10.1007/s40264-021-01065-z.Peer-Reviewed Original ResearchConceptsMajor adverse cardiovascular eventsHazard ratioIncident usersObservational studyCox model regression analysisAdjusted hazard ratioAdverse cardiovascular eventsReal-world registryInternational observational studyLong-term observational studyDisease-based registryRelevant clinical dataMACE riskUstekinumab exposureCardiovascular eventsPatient characteristicsPsoriasis patientsTreatment cohortsMethodological limitationsComparator groupSafety registryClinical dataRegistry dataModel regression analysisConclusionOur resultsCharacteristics of Patients with Psoriasis Treated with Apremilast in the Corrona Psoriasis Registry
Gottlieb A, Merola J, Cirulli J, Williams C, Linowski G, Paris M, Litman H, Guo N, Emeanuru K, McLean R, Cronin A, Strober B. Characteristics of Patients with Psoriasis Treated with Apremilast in the Corrona Psoriasis Registry. Dermatology And Therapy 2021, 11: 253-263. PMID: 33475970, PMCID: PMC7858993, DOI: 10.1007/s13555-020-00479-4.Peer-Reviewed Original ResearchCorrona Psoriasis RegistryPsoriasis RegistryMost patientsPsoriatic arthritisRegistry enrollmentApremilast patientsPhase 3 clinical studiesReal-world observational studyConcomitant systemic treatmentPrior biologic exposureCharacteristics of patientsTreatment of psoriasisQuality of lifeHigh rateIndex dateObservational registrySevere psoriasisSystemic medicationsAdult patientsBiologic therapyPatient characteristicsSystemic treatmentBiologic exposureModerate diseasePsoriasis patients
2020
The Skin Microbiome of Inverse Psoriasis
Chung J, Strober B, Weinstock G. The Skin Microbiome of Inverse Psoriasis. 2020, 203-215. DOI: 10.1002/9781119593058.ch10.Peer-Reviewed Original ResearchInverse psoriasisNon-lesion sitesSkin microbiomeSkin sitesHealthy skin sitesNon-lesional sitesPlaque psoriasis patientsSubtypes of psoriasisLongitudinal study designPsoriasis patientsIntertriginous sitesUnknown etiologyPsoriasisSkin diseasesStudy designMore subjectsPilot studyFurther studiesPatientsMicrobial differencesLesionsCohortMicrobiomeSubjectsPathogenesis
2019
Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council
Strober B, Ryan C, van de Kerkhof P, van der Walt J, Kimball A, Barker J, Blauvelt A, Members and Councilors I, Bourcier M, Carvalho A, Cohen A, Foley P, Evans C, Gisondi P, Griffiths C, El-Sayed M, Eschevarria C, Finlay A, Kalb R, Leonardi C, Lynde C, Murphy R, Murakami M, Okubo Y, Prens E, Puig L, Seyger M, Skov L, Terui T, Valenzuela F, Ward N, Wu J, Zheng M. Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council. Journal Of The American Academy Of Dermatology 2019, 82: 117-122. PMID: 31425723, DOI: 10.1016/j.jaad.2019.08.026.Peer-Reviewed Original ResearchConceptsPsoriasis severityInternational Psoriasis CouncilSystemic therapyTopical therapyConsensus statementUndertreatment of psoriasisBody surface areaPast treatment historyPsoriasis involvementPsoriasis patientsClinical studiesTreatment decisionsDelphi consensusEligibility criteriaTreatment historyPatientsSevere categoryTherapySeverity categoriesSeverity definitionsSeverityDichotomous definitionSeverity classificationDelphi approachUndertreatment
2018
Clinical Goals and Barriers to Effective Psoriasis Care
Strober BE, van der Walt JM, Armstrong AW, Bourcier M, Carvalho AVE, Chouela E, Cohen AD, de la Cruz C, Ellis CN, Finlay AY, Gottlieb AB, Gudjonsson JE, Iversen L, Kleyn CE, Leonardi CL, Lynde CW, Ryan C, Theng CT, Valenzuela F, Vender R, Wu JJ, Young HS, Kimball AB. Clinical Goals and Barriers to Effective Psoriasis Care. Dermatology And Therapy 2018, 9: 5-18. PMID: 30578464, PMCID: PMC6380974, DOI: 10.1007/s13555-018-0279-5.Peer-Reviewed Original ResearchPsoriasis patientsInternational Psoriasis CouncilResource-poor countriesPsoriasis careAutoimmune diseasesOptimal careEarly treatmentTreatment goalsInnovative therapiesTherapeutic efficacyClinical goalsPatientsTreatment barriersModerate formsDisease impactKey opinion leadersCareClinical sciencePsoriasisGreater gainsTherapyGreater understandingDisease
2017
Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75–89 response: results from two phase 3 studies of secukinumab
Elewski B, Puig L, Mordin M, Gilloteau I, Sherif B, Fox T, Gnanasakthy A, Papavassilis C, Strober B. Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75–89 response: results from two phase 3 studies of secukinumab. Journal Of Dermatological Treatment 2017, 28: 492-499. PMID: 28266243, DOI: 10.1080/09546634.2017.1294727.Peer-Reviewed Original ResearchConceptsQuality of lifeSeverity Index (PASI) 90 responseDLQI 0/1 responsePASI 75Skin clearancePASI 90Psoriasis AreaDermatology Life Quality Index responseGreater health-related qualityPatients' QOLGreater skin clearancePhase 3 studyHealth-related qualityNew biological therapiesRelevant therapeutic goalSevere psoriasisWeek 52Psoriasis patientsBiological therapyWeek 12Therapeutic goalsTrial dataSustained levelsIgA resultsClearance
2013
Community differentiation of the cutaneous microbiota in psoriasis
Alekseyenko A, Perez-Perez G, De Souza A, Strober B, Gao Z, Bihan M, Li K, Methé B, Blaser M. Community differentiation of the cutaneous microbiota in psoriasis. Microbiome 2013, 1: 31. PMID: 24451201, PMCID: PMC4177411, DOI: 10.1186/2049-2618-1-31.Peer-Reviewed Original ResearchCutaneous microbiotaLesion specimensCommon chronic inflammatory diseaseSkin typeChronic inflammatory diseasePsoriasis patientsPsoriatic patientsContralateral skinDifferential microbiotaInflammatory diseasesSkin colonizationHealthy controlsPsoriatic lesionsLesion siteDiagnostic significanceLesion samplesClinical diagnosisPsoriasis samplesPsoriasisSystemic levelsUseful predictorConclusionsOur resultsMicrobiotaPatientsLesions
2011
Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: Efficacy and safety results from an open-label study
Strober B, Poulin Y, Kerdel F, Langley R, Gu Y, Gupta S, Okun M, Papp K. Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: Efficacy and safety results from an open-label study. Journal Of The American Academy Of Dermatology 2011, 64: 671-681. PMID: 21414495, DOI: 10.1016/j.jaad.2010.03.009.Peer-Reviewed Original ResearchConceptsPhysician global assessmentSuboptimal responseSuboptimal therapyWeek 16Global assessmentPhase IIIb trialChronic plaque psoriasisOpen-label designOpen-label studyPrimary end pointPercentage of patientsNB-UVB phototherapySeverity Index scorePsoriasis clinical trialsTreatment of psoriasisDosage taperingIIIb trialPrior therapyPlaque psoriasisPsoriasis AreaPsoriasis flarePsoriasis patientsSafety profilePatient enrollmentClinical trials
2010
The treatment of moderate-to-severe psoriasis: prescreening and monitoring psoriatic patients on biologics.
Levine D, Strober B. The treatment of moderate-to-severe psoriasis: prescreening and monitoring psoriatic patients on biologics. Seminars In Cutaneous Medicine And Surgery 2010, 29: 28-34. PMID: 20430305, DOI: 10.1016/j.sder.2010.02.003.Peer-Reviewed Original ResearchConceptsSevere psoriasisUS FoodDrug AdministrationTumor necrosis factor-alpha inhibitorsNecrosis factor-alpha inhibitorsInterleukin-12/23 inhibitorsShort-term safetyT-cell modulatorDevelopment of biologicsBiologic therapyPsoriasis patientsPsoriatic patientsClinical trialsTherapeutic monitoringSpecific patientPatientsBiologicsMedicationsPsoriasisLong-term dataAdministrationTreatmentCurrent bodyInhibitorsEvidence
2008
Balancing Immunity and Immunosuppression: Vaccinating Patients Receiving Treatment with Efalizumab
Marmon S, Strober B. Balancing Immunity and Immunosuppression: Vaccinating Patients Receiving Treatment with Efalizumab. Journal Of Investigative Dermatology 2008, 128: 2567-2569. PMID: 18927537, DOI: 10.1038/jid.2008.291.Peer-Reviewed Original ResearchNational Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening
Kimball AB, Gladman D, Gelfand JM, Gordon K, Horn EJ, Korman NJ, Korver G, Krueger GG, Strober BE, Lebwohl MG, Foundation P. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. Journal Of The American Academy Of Dermatology 2008, 58: 1031-1042. PMID: 18313171, PMCID: PMC3716382, DOI: 10.1016/j.jaad.2008.01.006.Peer-Reviewed Original Research
2004
Etanercept for the treatment of psoriasis: combination therapy with other modalities.
Strober B, Clarke S. Etanercept for the treatment of psoriasis: combination therapy with other modalities. Journal Of Drugs In Dermatology 2004, 3: 270-2. PMID: 15176161.Peer-Reviewed Original ResearchMeSH KeywordsAcitretinAdultAnti-Inflammatory Agents, Non-SteroidalAntirheumatic AgentsArthritis, PsoriaticCyclosporineDose-Response Relationship, DrugDrug Therapy, CombinationEtanerceptFemaleHumansImmunoglobulin GKeratolytic AgentsMaleMiddle AgedPsoriasisReceptors, Tumor Necrosis FactorRecombinant Fusion ProteinsConceptsTumor necrosis factorTumor necrosis factor receptorWeekly doseRheumatoid arthritisPatients of psoriasisPlacebo-controlled studySevere plaque psoriasisSelf-administered medicationsJuvenile rheumatoid arthritisTreatment of psoriasisHuman fusion proteinNecrosis factor receptorPlaque psoriasisContinuous therapyPsoriasis AreaPsoriatic arthritisSystemic therapyPsoriasis patientsTreatment regimenClinical efficacyCombination therapyMedical historyClinical trialsNecrosis factorEtanercept